Combined class I histone deacetylase and mTORC1/C2 inhibition suppresses the initiation and recurrence of oral squamous cell carcinomas by repressing SOX2
- Resource Type
- ACADEMIC JOURNAL
- Authors
- Liang, Xueyi a, b, 1; Deng, Miao a, b, 1; Zhang, Chi a, b, 1; Ping, Fan a, b; Wang, Hongfei a, b; Wang, Yun b; Fan, Zhaona b; Ren, Xianyue b; Tao, Xiaoan a, b; Wu, Tong a, b; Xu, Jian c; Cheng, Bin a, b, ∗; Xia, Juan a, b, ∗∗
- Source
- In Cancer Letters 10 July 2019 454:108-119
- Subject
- Language
- English
- ISSN
- 0304-3835
- E-ISSN
- DOI
- 10.1016/j.canlet.2019.04.010
@@@@Highlights •Combined 4SC-202 (a novel selective class I histone deacetylases inhibitor) and INK128 (a selective mTORC1/C2 inhibitor) treatment exhibits synergistic effects on inhibiting cell growth and reducing ALDH1+ cancer stem cells in OSCC in vitro and in vivo.•Combined treatment significantly inhibits the initiation and recurrence of OSCC in rat models induced by 4NQO.•4SC-202 represses SOX2 expression through miR-429/miR-1181-mediated translational repression, while INK128 inhibits SOX2 via preventing cap-dependent mRNA translation.